| Ticker Details |
Denali Therapeutics Inc.
Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
|
| IPO Date: |
December 8, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.15B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.78 | 2.75%
|
| Avg Daily Range (30 D): |
$0.66 | 3.35%
|
| Avg Daily Range (90 D): |
$0.51 | 2.79%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.62M |
| Avg Daily Volume (30 D): |
1.4M |
| Avg Daily Volume (90 D): |
1.32M |
| Trade Size |
| Avg Trade Size (Sh.): |
69 |
| Avg Trade Size (Sh.) (30 D): |
66 |
| Avg Trade Size (Sh.) (90 D): |
66 |
| Institutional Trades |
| Total Institutional Trades: |
3,460 |
| Avg Institutional Trade: |
$2.75M |
| Avg Institutional Trade (30 D): |
$2.51M |
| Avg Institutional Trade (90 D): |
$2.78M |
| Avg Institutional Trade Volume: |
.1M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.8M |
| Avg Closing Trade (30 D): |
$4.54M |
| Avg Closing Trade (90 D): |
$4.32M |
| Avg Closing Volume: |
144.05K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-.74
|
$-.72
|
|
Diluted EPS
|
|
$-.74
|
$-.72
|
|
Revenue
|
|
$M
|
$M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
|
$-126.9M
|
$-124.12M
|
|
Operating Income / Loss
|
|
$-137.43M
|
$-134.96M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
|
$-50.24M
|
$84.26M
|
|
PE Ratio
|
|
|
|
|
|
|
